CGTX
Cognition Therapeutics, Inc. Common Stock
Nasdaq · usd
Cognition Therapeutics, Inc. Common Stock (CGTX) trades at $0.7097 (-1.27%) as of 2:03:32 PM EDT on Oct 26, 2026, -24.19% over the past month. Market cap is $68.35M, with 16.6 days to cover in short interest.
Stock performance
How Cognition Therapeutics, Inc. Common Stock (CGTX) stock has performed from one day to one year, with its 52-week range.
- 1D
- -1.22%
- 1W
- -2.39%
- 1M
- -24.19%
- YTD
- -47.41%
- 1Y
- -57.74%
- 52-wk range
- $0.55 – $1.83
Key statistics
Today's trading snapshot for CGTX: day range, open, previous close, volume and market cap.
- Day range
- $0.71 – $0.73
- Open
- $0.72
- Prev close
- $0.72
- Volume
- 135.87K
- Market cap
- $68.35M
- Shares out
- 95.09M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Cognition Therapeutics, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 2.07
- P/FCF
- —
- ROE
- -50.8%
- ROA
- -43.1%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Oct 23, 2026
8-K filings
Material corporate events Cognition Therapeutics, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Regulatory decisionOct 22, 2026
On October 22, 2026, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing the receipt of written feedback from the U.S. Food and Drug Administration (the "FDA") confirming alignment on key elements of a Phase 3 study in dementia with Lewy bodies.
- Regulatory decisionJun 24, 2026
On June 24, 2026, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing the receipt of written feedback from the U.S. Food and Drug Administration (the "FDA") following the Company's recent meeting with the FDA in May.
- Investor presentationJun 4, 2026
Attached as Exhibit 99.1 and furnished for purposes of Regulation FD is a presentation that Cognition Therapeutics, Inc. may use from time to time in presentations or discussions with investors, analysts, and other parties.
- Investor presentationMar 26, 2026
Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation that the Company may use from time to time in presentations or discussions with investors, analysts, and other parties.
- Regulatory decisionJan 27, 2026
On January 27, 2026, Cognition Therapeutics, Inc. (the "Company") issued a press release announcing the completion of its Tye C meeting with the U.S. Food and Drug Administration for zervimesine in dementia with Lewy bodies.
CGTX short interest
How heavily CGTX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 16.6
- Short interest
- 7.58M
- Avg volume
- 455.66K
As of · reported to FINRA twice monthly.
CGTX news
The latest news and headlines about Cognition Therapeutics, Inc. Common Stock (CGTX).
- James M. O’Brien Appointed Chief Financial Officer at MesoblastpositiveGlobeNewswire Inc.· Nov 17, 2025
- These Were the 5 Top-Performing Stocks in the Nasdaq Composite in August 2025positiveThe Motley Fool· Sep 3, 2025
- Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)positiveGlobeNewswire Inc.· Sep 2, 2025
- Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common StockpositiveGlobeNewswire Inc.· Aug 27, 2025
- Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business UpdatepositiveGlobeNewswire Inc.· Mar 20, 2025
Frequently asked questions
What is the Cognition Therapeutics, Inc. Common Stock (CGTX) stock price today?
Cognition Therapeutics, Inc. Common Stock (CGTX) is trading at $0.7097 (-1.27% on the day) as of 2:03:32 PM EDT on Oct 26, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Cognition Therapeutics, Inc. Common Stock?
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina.
What is the short interest in CGTX?
As of Sep 30, 2026, CGTX has 7.58M shares short and 16.6 days to cover.
What exchange is CGTX listed on?
Cognition Therapeutics, Inc. Common Stock (CGTX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.
Build with AI
Build an analysis of CGTX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a CGTX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.